ArticleFrontiers in public health2025
Sarcopenia and the frailty progression among Chinese: a longitudinal study.
Article in Frontiers in public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- The Clinical Characteristic and Prognostic Value of Frailty in Elderly COPD Patients.Journal of cachexia, sarcopenia and muscle · 2026Article
- Determinants of Early Quality-of-Life Improvement After Open Abdominal Wall Eventration Repair: A Large Single-Center Cohort Study Using the EuraHS-QoL Score.Journal of clinical medicine · 2026Article
- Malnutrition-Sarcopenia Syndrome in older adults: Causes, consequences, and countermeasures.EXCLI journal · 2026Review
- Longitudinal bidirectional associations among sarcopenia risk, social isolation, and frailty in Chinese older adults using an item response theory-derived frailty index.Frontiers in public health · 2026Observational
- Integrating sarcopenia into ICU-acquired weakness risk stratification: a machine learning-based prediction model for critical care.Frontiers in nutrition · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Previous studies primarily focused on baseline sarcopenia status, neglecting changes over time. This study aims to explore the association between changes in sarcopenia status and frailty progression, hypothesizing that transitions to possible sarcopenia or sarcopenia increase frailty risk, while recovery to non-sarcopenia reduces this risk. Methods: Using data from the China Health and Retirement Longitudinal Study (CHARLS), sarcopenia was evaluated at baseline and after 2 years using the AWGS 2019 criteria. Frailty was assessed with a 32-item frailty index. Cox regression and linear mixed models analyzed the association between sarcopenia transitions and frailty progression. Results: Participants who developed possible sarcopenia or sarcopenia faced a 56% higher frailty risk (HR 1.56, 95% CI 1.21-2.01) and a faster frailty index increase ( Conclusion: Transitions in sarcopenia status significantly affect frailty risk and progression. Worsening sarcopenia heightens frailty risk, whereas recovery diminishes it. These findings highlight the value of monitoring and addressing sarcopenia in middle-aged and older adults, offering potential to enhance quality of life and lower healthcare costs through targeted interventions.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.